219 related articles for article (PubMed ID: 20307616)
1. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas.
De Jesús ML; Hostalot C; Garibi JM; Sallés J; Meana JJ; Callado LF
Neurochem Int; 2010; 56(6-7):829-33. PubMed ID: 20307616
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Sánchez C; de Ceballos ML; Gomez del Pulgar T; Rueda D; Corbacho C; Velasco G; Galve-Roperh I; Huffman JW; Ramón y Cajal S; Guzmán M
Cancer Res; 2001 Aug; 61(15):5784-9. PubMed ID: 11479216
[TBL] [Abstract][Full Text] [Related]
5. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.
Luca T; Di Benedetto G; Scuderi MR; Palumbo M; Clementi S; Bernardini R; Cantarella G
Eur J Pharmacol; 2009 Aug; 616(1-3):16-21. PubMed ID: 19539619
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
Sim LJ; Hampson RE; Deadwyler SA; Childers SR
J Neurosci; 1996 Dec; 16(24):8057-66. PubMed ID: 8987831
[TBL] [Abstract][Full Text] [Related]
7. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis.
Berrendero F; Sánchez A; Cabranes A; Puerta C; Ramos JA; García-Merino A; Fernández-Ruiz J
Synapse; 2001 Sep; 41(3):195-202. PubMed ID: 11391780
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
9. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.
Selley DE; Rorrer WK; Breivogel CS; Zimmer AM; Zimmer A; Martin BR; Sim-Selley LJ
J Neurochem; 2001 May; 77(4):1048-57. PubMed ID: 11359870
[TBL] [Abstract][Full Text] [Related]
10. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.
Qamri Z; Preet A; Nasser MW; Bass CE; Leone G; Barsky SH; Ganju RK
Mol Cancer Ther; 2009 Nov; 8(11):3117-29. PubMed ID: 19887554
[TBL] [Abstract][Full Text] [Related]
11. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development.
Shoeib AM; Yarbrough AL; Ford BM; Franks LN; Urbaniak A; Hensley LL; Benson LN; Mu S; Radominska-Pandya A; Prather PL
Life Sci; 2021 Nov; 285():119993. PubMed ID: 34592231
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
14. Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.
Dennis I; Whalley BJ; Stephens GJ
Br J Pharmacol; 2008 Jul; 154(6):1349-58. PubMed ID: 18493244
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
16. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
Thomas A; Stevenson LA; Wease KN; Price MR; Baillie G; Ross RA; Pertwee RG
Br J Pharmacol; 2005 Dec; 146(7):917-26. PubMed ID: 16205722
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
Breivogel CS; Griffin G; Di Marzo V; Martin BR
Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice.
Berrendero F; Mendizábal V; Murtra P; Kieffer BL; Maldonado R
Eur J Neurosci; 2003 Oct; 18(8):2197-202. PubMed ID: 14622180
[TBL] [Abstract][Full Text] [Related]
20. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
